# Advances in Detecting Cystic Echinococcosis in Intermediate Hosts and New Diagnostic Tools: A Literature Review

## TL;DR

This paper reviews recent advances in diagnosing cystic echinococcosis, a zoonotic disease, with a focus on new tools like nanobiosensors that improve detection and treatment outcomes.

## Contribution

The paper highlights the potential of nanobiosensors to enhance CE diagnosis and integrate human and veterinary diagnostics.

## Key findings

- Nanobiosensors offer improved sensitivity and portability for CE detection in resource-limited settings.
- Serological tests like ELISA and immunoblotting are effective for diagnosing CE by detecting antibodies.
- Nanobiosensors outperform conventional methods in detecting hydatid cysts and specific biomarkers.

## Abstract

Despite its importance to global health, hydatid disease remains difficult to diagnose and control without accurate and accessible diagnostic tools. A One Health approach is necessary for cystic echinococcosis (CE), a zoonotic disease affecting humans and animals. Antibodies detection of Echinococcus granulosus by Enzyme-Linked Immunosorbent Assay (ELISA) and immunoblotting can confirm CE diagnosis, particularly in cases where other techniques may fail. A correct and early diagnosis is fundamental to determining the treatment outcome of the CE patient. Nanotechnologies and nanobiosensors have advanced diagnostic capabilities in recent years. The development of nanobiosensors has the potential to bridge the gap between human and veterinary diagnostics, enabling more integrated surveillance and control strategies. Nanobiosensors present a significant step forward in CE detection in resource-constrained settings when integrated into field-based surveillance systems. Due to their portability and ease of use, these sensors can be used as point-of-care diagnostic devices, enabling timely, decentralized diagnosis. Ensuring access to advanced laboratory tools in regions with limited access is crucial.

Cystic echinococcosis (CE) is a zoonotic disease affecting humans and animals. Despite a lack of clarity about many details of parasite–intermediate host interactions, the nature of the immune responses triggered by hydatid infection has revealed new perspectives. This study discusses the latest advances in elucidating the immunologic mechanism of echinococcosis and its detection and potential approaches to enhance serodiagnosis accuracy. Moreover, nanobiosensors have been evaluated according to their potential to improve treatment efficiency and aid in an early diagnosis of cystic echinococcosis. The serum of an intermediate host can diagnose CE by analyzing antibodies induced by Echinococcus granulosus. Among the most notable features of this method are its noninvasive ability and high sensitivity, both of which make it an excellent tool for clinical diagnosis. Several serological tests, including ELISAs and immunoblotting, can detect these antibodies to assess the disease’s state and determine the treatment outcome. A thorough understanding of what cross-reactivity means and the stage of the disease are crucial to interpreting serological results. Nanobiosensors have also proven better than conventional biosensors in detecting hydatid cysts. Additionally, they are highly sensitive and versatile when detecting specific biomarkers, improving diagnostic accuracy. These immunomodulatory molecules, induced by E. granulosus, are a good candidate for diagnosing cystic echinococcosis because they alter intermediate host immune responses. Hydatid cyst detection is also enhanced through nanobiosensors, which provide better accuracy.